44 research outputs found
Multiple binomial logistic regression analysis to predict 30-day mortality.
<p>Patients with serum MDA higher than 2.27 nmol/mL (n = 23) presented higher 30-day mortality (Hazard ratio = 2.9; 95% CI = 1.31–6.33; p = 0.005) than patients with lower levels (n = 27) in the survival analysis (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0125893#pone.0125893.g003" target="_blank">Fig 3</a>).</p><p>Multiple binomial logistic regression analysis to predict 30-day mortality.</p
Receiver operation characteristic analysis using serum malondialdehyde levels as predictor of mortality at 30 days.
<p>Receiver operation characteristic analysis using serum malondialdehyde levels as predictor of mortality at 30 days.</p
Serum malondialdehyde levels in severe malignant middle cerebral artery infarction patients and healthy controls.
<p>Serum malondialdehyde levels in severe malignant middle cerebral artery infarction patients and healthy controls.</p
Clinical and biochemical characteristics of 30-day survivor and non-survivor MMCAI patients.
<p>P 25–75 = percentile 25<sup>th</sup>-75<sup>th</sup>; APACHE II = Acute Physiology and Chronic Health Evaluation; aPTT = activated partial thromboplastin time; GCS = Glasgow Coma Scale; INR = international normalized ratio; PaO<sub>2</sub> = pressure of arterial oxygen/fraction inspired oxygen; FIO<sub>2</sub> = pressure of arterial oxygen/fraction inspired oxygen; MDA = Malondialdehyde</p><p>Clinical and biochemical characteristics of 30-day survivor and non-survivor MMCAI patients.</p
Characteristics of healthy controls and patients with severe malignant middle cerebral artery infarction.
<p>Characteristics of healthy controls and patients with severe malignant middle cerebral artery infarction.</p
Kaplan-Meier curves showing the cumulative proportion of survival patients at 30 days and 6 months according to the presence of 4G/4G vs other genotypes of PAI-1 genetic polymorphism.
<p>Kaplan-Meier curves showing the cumulative proportion of survival patients at 30 days and 6 months according to the presence of 4G/4G vs other genotypes of PAI-1 genetic polymorphism.</p
Characteristics of severe septic patients according to genotype in the PAI-1 gene.
<p>COPD = chronic obstructive pulmonary disease; PaO<sub>2</sub>/FIO<sub>2</sub> = pressure of arterial oxygen/fraction inspired oxygen; INR = International normalized ratio aPTT = Activated partial thromboplastin time; APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sepsis-related Organ Failure Assessment.</p><p>Characteristics of severe septic patients according to genotype in the PAI-1 gene.</p
Early and late mortality according to genotype in the PAI-1 genetis polymorphis.
<p>Early and late mortality according to genotype in the PAI-1 genetis polymorphis.</p
Multiple logistic regression analyses to predict 6-month mortality.
<p>Multiple logistic regression analyses to predict 6-month mortality.</p
Correlation of serum caspase-cleaved citokeratin (CCCK)-18 levels with serum levels of TNF-α, interleukin-6, interleukin-10, and lactic acid, and with SOFA and APACHE-II scores.
<p>TNF = tumor necrosis factor; SOFA = Sepsis-related Organ Failure Assessment score<b>;</b> APACHE = Acute Physiology and Chronic Health Evaluation (APACHE)-II score; rho = Spearman’s rank correlation coefficient.</p><p>Correlation of serum caspase-cleaved citokeratin (CCCK)-18 levels with serum levels of TNF-α, interleukin-6, interleukin-10, and lactic acid, and with SOFA and APACHE-II scores.</p